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Osteoarthritis (OA) is one of the most common complaints encountered in the primary 
care setting today, and predominantly affects older patients. The increase in our aging population 
results in an increased frequency of OA overall, and hence, heightened demands on the 
healthcare system. To better understand osteoarthritis and how it impacts healthcare, it is 
important to understand the pathophysiology behind the disease. OA is a progressive disease that 
slowly destroys every structure in a joint including bone, and soft tissues, such as articular 
cartilage, joint capsule, and ligaments.1   Furthermore, it is a chronic disease that can cause 
patients a considerable amount of pain and disability. Over time, OA causes the loss of articular 
cartilage in most joints, causing joint pain as the bones in the joint move across one another.1  
Without the protection of the articular cartilage, chronic inflammation begins to develop around 
the bone causing further destruction of the joint, resulting in pain and limiting mobility. This 
destruction of the joint causes osteophyte formation, which narrows the joint space and 
eventually limits the joint’s range of motion. As the joint becomes increasingly calcified and the 
cartilage is further destroyed, the patient experiences increased pain and a reduced quality of life 
(QOL).1 
Many treatment options are available to these patients; however, most are inadequate for 
long-term effectiveness and safety. Available therapies include physical therapy, OTC 
medications such as acetaminophen and NSAIDs, steroid injections, hyaluronic injections, and 
partial or total joint replacement surgeries.2  Conventionally, OA is treated with analgesics, anti-
inflammatory medications, physical therapy, and corticosteroid or hyaluronic acid injections in 
the affected joint. Although both types of injections are feasible options, in practice not all 
patients see improvement from steroids or hyaluronic acid.2  Because of the low efficacy of 
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conventional injections and the recent push from patients for more natural treatment alternatives, 
new technologies have been developed over the past decade to alleviate pain and improve 
function in patients. Platelet-rich plasma, or PRP, is a relatively recent and promising new 
therapy for OA that is more natural and possibly more effective than conventional OA therapy.  
The proposed mechanism for PRP is that the growth factors and healing enzymes in a patient’s 
blood (when isolated, concentrated, and injected into the affected or damaged joint) decrease 
joint inflammation, thus reducing pain and improving QOL. PRP therapy first starts with 
drawing blood from the patient. Next, the patient’s blood is spun down and separated with a 
centrifuge. The blood separates with the red blood cells near the bottom and white blood cells 
and platelets near the top. The platelets accumulating in this layer contain many different growth 
factors that can be collected and injected into the patient’s joint at a much higher concentration. 
PRP usually contains over 20 different types of enzymes, proteins, peptides and growth factors 
such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-beta), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF) platelet factor 4, interleukin-
1, and platelet derived angiogenesis factor.3  In brief, the PRP injections contain enzymes and 
factors that promote healing, reduce inflammation, and promote regeneration of cartilage in 
joints.3  These growth factors act on chondrocytes to help promote synthesis of the cartilage 
matrix, increase cell turnover, cell growth, cell migration, as well as promote protein 
transcription.3  The premise of PRP’s benefit is that its growth factors will set off a cascade of 
natural healing and regeneration of tissue in the damaged joint. 
Not all PRP is made equally. Preparation methods and combinations of PRP vary widely 
in practice because a standard protocol has not yet been established. PRP also varies due to the 
different systems used to procure this solution. PRP is obtained by either a one-spin or a two-
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spin process.3  Systems that use a one-spin process separate the blood sample into two layers: 
RBCs with WBCs, and platelets. The platelet concentrations from the one-spin systems are 
usually 1-3 times greater than in whole blood and take less time to concentrate. This shorter 
preparation time removes the need for adding an anticoagulant to the blood in order to prevent 
clotting from occurring during the blood removal procedure and when the PRP is injected into 
the desired joint. Two-spin systems separate the blood into three distinct layers: RBCs, a buffy 
coat layer with platelets and WBCs, and a platelet depleted plasma layer. The layer desired in a 
the two-spin system is the buffy coat layer which typically contains five times the concentration 
of platelets than a one-spin system. Preparation times, however, are at least 30 minutes or more, 
which means these samples require an anticoagulant to prevent clotting during the process.3 
Patients rarely have any adverse side effects from these injections. Because patients are 
receiving their own blood, the risk of any immunologic reaction occurring, if existent, is 
minimized. Nonetheless, as with any other injections, the risks of injection site reaction, 
infections and bleeding are still present. To prevent these potential complications from 
happening, PRP injections should be administered using aseptic technique.  
  Whether the complex and time-intensive requirements for administering PRP warrants its 
use for intra-articular (IA) therapy in OA is in question and should be examined. If PRP is at 
least or even more effective than corticosteroids or hyaluronic acid (HA) for relieving pain and 
restoring function, then it can be recommended with confidence to OA patients who are 
appropriate candidates for intra-articular injections. In addition, if its beneficial effects are more 





Overwhelming preliminary evidence supports IA PRP injection as a possible option for 
treating OA in order to reduce pain and improve function. In a study by Guvendi et al, 57 
patients with knee OA were randomized into three IA groups; group one received one 
corticosteroid injection, group two received one PRP injection, and group three received three 
PRP injections four weeks apart.4  All groups were followed at two-month and six-month marks 
after the injection. Seven patients were lost to follow up; two in the corticosteroid group and five 
in the three-PRP injection group. A visual numeric scale and the Western Ontario and McMaster 
Universities Arthritis Osteoarthritis Index (WOMAC) were used to evaluate pain, stiffness, and 
function, while the Lequensne scale was used to assess physical function. For all injections, 
visual numeric scores showed a significant reduction in pain at rest, at night, and with 
movement. The 3-PRP injection group, however, showed the greatest improvement at the two-
month mark. At the six-month follow-up, pain scores still reflected improvements compared with 
baseline evaluations. WOMAC scores also declined in the three groups but both PRP injection 
groups showed greater improvement than corticosteroids. The difference in WOMAC scores 
between three-PRP and one-PRP groups at the six-month follow-up, however, was not 
statistically significant. Nonetheless, PRP injections were found to be effective for at least six 
months in the patients who participated for the full length of the study. This evidence highlights 
that compared with steroid injections, PRP injections for Knee OA had more durable (longer-
lasting) effects on pain and QOL. The study had no reports of edema or pain after any of the 
injections; however, they did have one participant in the single PRP injection group that 
experienced mild erythema which eventually resolved after six hours of cold therapy.4   For these 
reasons, Guvendi et al. proposed that PRP IA injection is a viable and safe alternative to 
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corticosteroids for OA of the knee.4  While the study showed great significance in better 
WOMAC and Lequensne scores by using PRP injections, it was limited by a small sample size, 
and brief follow up time. The researchers also state that due to the lack of a placebo and a control 
group, the participants were not blinded in this study. The study also suggested that accuracy in 
injection placement could be improved by using ultrasound guidance techniques.4  
            Glynn et al. researched the feasibility of relieving OA pain with PRP injections as well as 
whether this therapy could be administered competently in outpatient clinics.5   Twelve patients 
with OA associated pain in their knees were treated with PRP injections 3 times in 4 week 
intervals. Follow-up with the patients began 4 weeks after the last injection was placed. All 12 
demonstrated improvement in their pain scores using an intermittent and constant osteoarthritis 
pain (ICOAP) questionnaire for knee arthritis, including two patients who reported complete 
resolution of pain at the four month follow up.5   Outcomes were measured using the EURO-Qol 
Visual Analogue Scale (EQ-VAS) healthy utility which assess a patient’s overall health from 
“worst possible” to “best possible” on a visual analog scale. In addition, patient specific goals 
were set to determine whether true mobility and function were achieved. The goals set by these 
patients included being pain free, walking normally without aids, decreasing joint stiffness, and 
preventing joint replacement surgery.5   Eleven out of the 12 patients receiving PRP injections in 
this study reported success in achieving their specific goals at the four-month follow up. In 
addition, the average reduction in pain reported was significant at 29%, and the average health 
utility score increased significantly as well.5   The chief finding in this study suggested that PRP 
injections are a viable treatment option to provide patients in an outpatient primary care setting. 
The study employed a limited amount of exclusion criteria which allowed more of a variety of 
patients to participate in the study however, the study only followed 12 participants. The 
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researchers suggest that due to the limited exclusion criteria the study may be easily 
implemented in a larger population. Major limitations with this study was the very small sample 
size of 12 participants with no loss throughout the study, participants were all of one single race, 
and the study did not use a control group. The study also reported no major adverse reactions 
occurring during the study due to the injections.5 
In a study with longer follow up by Dhillon et al., 90 patients with degenerative changes 
in the knee were evaluated 24 months after treatment with PRP injections.6   Both efficacy and 
durability of pain were examined. This study was an additional follow up investigation to the 
same group of participants who received PRP injections over a 12-month period. 91 patients 
participated in the initial PRP investigation, however one patient was lost to follow-up  and did 
not participate in the 24-month evaluation. International Knee Documentation Committee 
(IKDC) subjective knee evaluation forms (knee-specific and patient reported) and EQ-VAS 
scores were used to measure knee symptoms. The results of these questionnaires revealed that all 
the parameters which initially improved, had worsened at the 24-month mark; IKDC scores fell 
from 67% to 59%. Despite the decrease in improvements over time, these scores were better than 
the patients’ baseline scores before receiving any PRP injections. Furthermore, the study showed 
that the scores did not drop as much in younger patients nor in those with milder forms of OA. 
For most of these patients, the median duration of improvement was around the nine-month 
mark.6   Although PRP injections were found to be a viable treatment modality for improving 
OA knee pain, the duration of PRP’s benefits was limited. Notwithstanding this constraint PRP 
injections’ maximal effectiveness averaged 9 months, and patients’ symptoms improved vastly 
from their baselines. Major weaknesses in this study were the lack of  control group and  the 
omission of knee functional assessments.  
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In a meta-analysis by Zhang et al. WOMAC and VAS (visual Analog Scale for pain) 
scores were compared after PRP injections versus hyaluronic acid (HA) injections for the 
treatment of knee OA.7  Three prospective observational and 10 randomized controlled trials 
with 1,520 participants in total were examined, with the majority of the participants (about 91%) 
in the early stages of OA. According to WOMAC scores, PRP injections reduced pain more 
effectively than HA injections at 6-month and 12-month follow ups.7  VAS scores, however, 
showed no significant difference between the two types of injections at the three-month mark.7 
The findings from this meta-analysis revealed that while PRP injections were helpful, they may 
not have been be superior to HA injections. The absence of significance could have been due to 
differences among the studies in the quality of the preparations and the concentrations of the 
growth factors in the PRP injections. The most recent data from multiple resources were 
standardized in this review and found that overall PRP injections were beneficial. More studies 
are needed, however, to prove PRP’s superiority to HA injections. The significant heterogenicity 
in each investigation’s calculation and the wide variety of evaluation tools were limitations in 
this meta-analysis.   
Finally, in a study by Joshi Jubert et al, a single PRP injection was found to be effective 
for reducing pain, and improving activities of daily living and QOL.8   This study was a 
prospective, randomized, double-blinded clinical trial and focused mainly on patients with 
advanced OA. Sixty-five patients in total were randomized into either a PRP group (35) or a 
corticosteroid group (30), with only one participant lost from the PRP group.8   Patients were 
evaluated using the VAS scale at one month to asses pain reduction. Additionally, the Knee 
Injury and Osteoarthritis Outcome Score (KOOS) and the Short-Form 36 (SF-36) at one, three 
and six months after the injection were used to measure function and quality of life. The VAS 
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scores decreased in both groups, but no significant difference was found between steroid and 
PRP injections.8  The KOOS scores and the SF-36 results, however, were better in the PRP 
group compared with the corticosteroid group at all follow up intervals, showing that PRP 
injections gave patients better qualities of life.8   While most of the studies dealt with early OA, 
this RCT’s findings suggested that even in the later stages of OA, PRP injections can still be 
beneficial for patients who wish to avoid surgery. The limited sample size and hence the inability 
to rule out a type II error statistically, was a major limitation of this trial.   
In addition to the success with PRP IA injections for knee OA, this therapy was shown to 
alleviate pain and improve function in patients with lumbar discogenic pain. Akeda et al. found 
that a single PRP injection in the lumbar spine produced favorable results in patients with 
discogenic low back pain.9   In order to qualify for participation, patients must have been 18 
years old or older and must have had established chronic low back pain with evidence of OA or 
degenerative joint disease by MRI, but without radiculopathies.9   The results were remarkable 
despite the small sample size of 14 patients. With just one injection, 71% of the patients noted at 
least a 50% reduction of low back pain according to VAS scores.9   Patients also experienced 
improvement of disability scores measured by Roland-Morris Disability Questionnaire (RDQ): 
79% of patients had 50% or more improvement of function in their daily lives.9  Two 
participants experienced temporary paresthesias in their lower extremities; however, those 
symptoms disappeared after 7 days and no other apparent adverse effects were noted.9  This trial 
provided evidence that PRP injections were a safe, feasible and effective treatment option for 
patients suffering from lumbar discogenic pain. Thus, PRP could be a viable option for younger 
patients who are not ready and are generally not recommended for spinal fusion surgeries.  An 
investigation with a large sample size would further elucidate the significance of these findings.  
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In another pilot study, Bhatia et al. included patients suffering from lumbar back pain for 
(with or without a history of radiculopathy) for at least four weeks who were 18-65 years old, 
had a positive straight leg raise test (SLRT), and were not responding to conventional treatments 
such as steroid injections, physical therapy, and spinal manipulation.10 Patients were evaluated 
with VAS, Modified Oswestry Low Back Pain Disability Questionnaire (MODQ) scores, SLRT 
and neurology exams before and after the PRP injections.10  Ten patients were followed for at 
least three months. Findings included gradual improvement of VAS scores, MODQ scores, and 
SLRT after the procedure. Within three months, all VAS scores were under five, MODQ scores 
were reduced by 30% and SLRT improved to 70 degrees.10 Results were sustained for six 
months in more than half of the patients. Both back pain trials clearly demonstrated that PRP 
injections were efficacious in reducing pain as well as improving mobility in patients with low 
back pain.  
In all the studies cited above, researchers concluded that PRP injections greatly benefit 
patients with osteoarthritis, specifically by reducing pain and improving function. PRP injections 
were shown to be superior to corticosteroids and hyaluronic acid for improving all the measured 
scores for pain, function and QOL. PRP injections were especially superior to all other 
interventions for achieving short term pain relief.  
While research on PRP joint injections is still relatively new, some important questions 
still need to be answered. Future research to determine the long-term side effects of these 
injections should be planned. Other questions about PRP’s efficacy necessitate further 
investigation. How long will the injections last? Do the injections lose efficacy over time? Is a 
specific amount of PRP injected into the joint more effective? Some researchers, even now, are 
starting to test the different growth factors in PRP to see which ones are the most effective and 
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which ones in combination with another could lead to better results. The final and most 
significant question of all is whether injecting PRP early enough in the OA disease process 
would not only slow progression but also potentially halt it and perhaps even reverse the 
damaging effects that OA has on joints. Examining the roles of growth factors and their 
concentration levels in PRP injections may help answer that question. 
The major limitation to PRP is cost. Presently, it is extremely expensive and few clinics 
currently have the technology, education, and means to offer PRP as a treatment. These obstacles 
to making PRP readily available makes PRP inaccessible to the majority of patients who need it. 
Insurance companies are not covering any of the treatments since the research is still being done 
on whether it is an efficacious treatment option. However, with more research, over time the 
overall cost could decrease as insurance companies discover that PRP injections could be much 
less expensive than surgeries and just as, if not more, efficacious as steroid injections. Another 
limitation to PRP therapy is the time it takes to prepare and administer as this process can be 
lengthy. Patients who have been accustomed to quick in and out visits to receive a steroid 
injection may be surprised PRP injections may take up to an hour in the office. Another obstacle 
and limitation to PRP is the requirement for much more advanced equipment and training for this 
procedure. Providers and hospitals who want to offer PRP injections as a treatment option will 




Platelet rich-plasma injections are a viable alternative therapy for patients who are 
suffering from chronic osteoarthritis pain and disability. PRP therapy appears to be safe and has 
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been shown to improve pain and disability scores at different joints in multiple studies. More 
research is needed to evaluate the true mechanism behind PRP injections. Longer term studies 
are needed to confirm the durability of the beneficial effects from these injections. Larger and 
different population samples are also needed to prove PRP injections will work for the general 
population and not just for a specific subset of patients. 
For treating OA, PRP injections have already changed clinical practice. Clinicians can 
now use PRP injections as a conventional treatment before patients resort to a total joint 
replacement or spinal fusion surgeries; both of which are costly, not always effective, and like all 
surgeries have significant risks, dangers, and challenges. With further research PRP injections 
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